BJH - 2018, issue Abstract Book BHS, february 2018
E. Collinge , C. Graux MD, PhD, M. André MD, H. Labussière-Wallet , M. Michallet , G. Salles
BJH - 2018, issue Abstract Book BHS, february 2018
O. Stas , E. Mourin MD, J. Depaus , F-X. Hanin , I. Theate , M. André MD
BJH - volume 8, issue Abstract Book BHS, february 2017
A. Smet , V. Van Hende MD, M. André MD, C. Bonnet MD, PhD, G. Bries MD, PhD, V. De Wilde MD, PhD, H. Demuynck MD, N. Meuleman MD, PhD, W. Schroyens MD, PhD, A. Van Hoof MD, PhD, M. Giordan , L. de Vos , A. Janssens MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
G. Verhoef MD, PhD, M. André MD, J. Imschoot , P. Graas , D. Bron MD, PhD
BJH - volume 8, issue Abstract Book BHS, february 2017
S. Bailly MD, M-C. Vekemans MD, B. Chatelain PharmD, M. André MD, T. Vander Borght , L. D’Hondt , L. Faugeras , G. Verstraete , J. Devreux , G. Di Prinzio , S. Lefevre
BJH - volume 7, issue 5, october 2016
P. Mineur MD, C. Doyen MD, PhD, N. Straetmans MD, PhD, K. Van Eygen MD, D. Pranger MD, A. Bosly MD, PhD, M. André MD, T. Devos MD, PhD, L. Knoops MD, PhD, On behalf of the MPN Belgian Hematological Society subcommittee
This article describes the Belgian register of chronic myeloid leukaemia patients who have stopped their treatment with imatinib in conditions comparable to the French STIM trial results: 44% remained in major molecular response off therapy; relapses appear rapidly after stopping imatinib and are responsive when the treatment is resumed.
(BELG J HEMATOL 2016;7(5):184–6)
Read moreBJH - volume 7, issue 2, april 2016
V. De Wilde MD, PhD, D. Dierickx MD, PhD, W. Schroyens MD, PhD, E. Van den Neste MD, PhD, C. Bonnet MD, PhD, M. André MD, A. Janssens MD, PhD, V. Van Hende MD, A. Van Hoof MD, PhD
Primary central nervous system lymphoma is a rare form of extranodal B cell lymphoma of the brain, the eyes, the meninges or the spinal cord in the absence of systemic lymphoma. The management of primary central nervous system lymphoma remains controversial, which is related to the rarity of the cases and the small number of controlled studies available. The present consensus report provides the guidelines proposed by the Belgian Hematology Society Lymphoproliferative Working Party for treating immunocompetent adult patients with primary central nervous system lymphoma.
(BELG J HEMATOL 2016;7(2):69–78)
Read more
Top
